800P - VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): a retrospective analysis of the use of vinflunine i...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Urothelial Cancers
Presenter Syed Hussain
Citation Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373
Authors S. Hussain1, J. Ansari2, R. Huddart3, D. Power4, J. Lyons5, J. Wylie5, M. Vilarino-Varela6, N. Elander7, R. McMenemin8, L. Pickering9, G. Faust10, S. Chauhan7, R. Jakson7
  • 1Molecular And Clinical Cancer Medicine, University of Liverpool-Royal Liverpool University Hospital,, L69 3GL - Liverpool/GB
  • 2Clinical Oncology, Beatson West of Scotland Cancer Centre Gartnavel General Hospital, Glasgow/GB
  • 3Clinical Oncology, Royal Marsden Hospital Institute of Cancer Research, SM2 5NG - Sutton/GB
  • 4Medical Oncology, Cork University Hospital, Cork/IE
  • 5Clinical Oncology, The Christie NHS Foundation Trust, Manchester/GB
  • 6Department Of Radiotherapy/oncology, Royal Free Hospital School of Medicine, London/GB
  • 7Molecular And Clinical Cancer Medicine, University of Liverpool-Royal Liverpool University Hospital,, Liverpool/GB
  • 8Clinical Oncology, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle upon Tyne/GB
  • 9Oncology, St George's Hospital NHS Trust, SW17 0QT - London/GB
  • 10Clinical Oncology, Northampton General Hospital NHS Trust, Northampton/GB



There is no standard of care currently in UK for second line chemotherapy for patients with advanced TCC. Vinflunine is approved for TCCU for patients who have failed a platinum-based regimen and is now the standard chemotherapy in 2nd line in Europe based on large phase III randomised trial data showing 2.6 months survival advantage. ESMO guidelines recommended it as the only option for patients in the 2nd line setting. Vinflunine is not currently available in NHS practice in UK as it is not on the approved list of drugs on cancer drug fund.


Data are collected retrospectively on patients who received Vinflunine as a 2nd line treatment through FOCP. The dose of Vinflunine was 320/280/240 mg/m2 every 3 weeks as per the SPc. The aim was to document the toxicity, radiological RR and OS in a real life setting within the FOCP.


Data were collected on 49 patients from 9 sites across the UK and Ireland (median age: 64 (IQR: 57-70) years, 33 males ). All patients had advanced metastatic TCCU. Thirteen patients had bone or liver metastases, 4 patients had PS 2 and 11 patients had HB


Real life data reveal a median OS of 9.1 m by ITT for all patients which is consistent with real life data from Europe (Spanish, German and French) presented at ESMO 2013. Toxicity has been further reduced with the use of prophylactic laxative and oral antibiotics. Vinflunine is an efficient and tolerable second line treatment in advanced TCCU.

Clinical trial identification

Legal entity responsible for the study

University of Liverpool


Pierre Fabre


All authors have declared no conflicts of interest.